We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Cost Considerations in the Evaluation and Treatment of Colorectal Cancer.
Current Treatment Options in Oncology 2015 August
OPINION STATEMENT: As the cost of cancer care in the United States continues to climb at an alarming rate, it is critically important for the oncology community to begin embracing interventions that provide value to patients and society. This is particularly important in the field of colorectal cancer, where many new high-priced drugs have emerged over the past several years. While adjuvant chemotherapy (FOLFOX and capecitabine) has been shown to fall within accepted thresholds for cost-effectiveness, many interventions in the metastatic setting have not. Bevacizumab in the first- and second-line settings as well as EGFR inhibitors across all lines of therapy have been associated with unfavorable cost-effectiveness ratios in several studies conducted in the United States and other countries. A key strategy in improving the cost-effectiveness of CRC treatment in the advanced setting will therefore be to identify predictive biomarkers (e.g., RAS mutation) for therapeutic response to existing drugs as well as drugs in development so that high-priced therapies can be administered to patients most likely to benefit and avoided in those who would not.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app